Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://innovativemedicine.jnj.com/emea/
Sanofi Oncology
At Sanofi Oncology, we are advancing our ambition to make Sarclisa® (isatuximab) a best‑in‑class anti‑CD38 antibody, supported by positive results from eight phase 3 studies across the multiple myeloma treatment continuum.
Multiple myeloma remains incurable, and Sarclisa was developed to address critical unmet needs with the ultimate goal of improving long-term outcomes for multiple myeloma patients. We are committed to pursuing the advancement of Sarclisa through our patient-centric clinical development programs that aim to bring it to more patients and intercept the disease earlier in the treatment journey.
Approved in over 50 countries, across four indications, and prescribed to more than 60,000 people with newly diagnosed or relapsed/refractory settings, Sarclisa reflects our commitment to extending lives, easing burden, and restoring hope for those affected by cancer and living with the disease.
#weneversettle
SANOFI SOCIAL CHANNELS & LINKS
GSK
At GSK, we’re advancing a promising portfolio of innovative oncology medicines to deliver practice-changing impact, expanding rapidly beyond our focus in haematological and gynaecological cancers into lung and Gl cancers, and other solid tumours.
For further information, please visit us at:
https://www.linkedin.com/company/gsk
https://x.com/GSK
https://bsky.app/profile/gsk.bsky.social
https://www.instagram.com/gsk/
https://www.facebook.com/GSK
https://www.youtube.com/GSK
https://www.gsk.com/en-gb/media/rss-feeds/
Bristol Myers Squibb
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are motivated by the power of science, with a legacy of pursuing bold science across oncology, hematology, cardiovascular, immunology and neuroscience. We’re accelerating the development of new medicines with differentiated research platforms and leading technology to define what’s possible for the future of medicine and the patients we serve.
https://www.globalbmsmedinfo.com/
© 2026 Bristol-Myers Squibb Company
Gilead | Kite
Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.
Cell Therapy Hub link: CellTherapyHub.com
Regeneron
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center. Visit www.Regeneron.com to learn more.
Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.
Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.
The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
For more information see: www.oncopeptides.com
Adaptive Biotechnologies
Adaptive Biotechnologies is a leader in the field of immunosequencing, transforming the understanding of the immune system through cutting-edge technologies.
clonoSEQ® is a next-generation sequencing (NGS) test that enables precise and sensitive measurement of minimal residual disease (MRD) in blood cancers, such as leukemia and lymphoma. This test provides clinicians with valuable insights into disease monitoring, relapse detection, and treatment response. Now available in Europe, clonoSEQ empowers healthcare providers with advanced tools for better patient outcomes in the fight against hematologic malignancies.
Adaptive Biotechnologies
1165 Eastlake Ave E, Seattle WA 98109 USA
www.adaptivebiotech.com
[email protected]
Sebia
Sebia is a global leader in specialized in vitro diagnostics, providing instruments, reagents, and innovative solutions for the screening and monitoring of a wide range of diseases. Our expertise covers oncology (with a strong focus on Multiple Myeloma), diabetes, autoimmune and infectious diseases, as well as various rare disorders.
In the field of Multiple Myeloma, Sebia offers a unique and comprehensive portfolio that covers the full continuum of M‑protein testing—from initial detection to minimal residual disease (MRD) assessment. This includes SPE, IFE, FLC, and blood‑based MRD testing.
Our mission is to deliver powerful tools that translate what is happening inside a patient’s body into clear, reliable, and interpretable information, supporting healthcare professionals in making confident clinical decisions.
Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
Amgen
One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
Tel: +1 805-447-1000
www.amgen.com (can refer to “contact us” on this website for different email contacts)
Menarini Stemline
Menarini Stemline is committed to making a difference in cancer patients’ lives. We invest in developing precision medicine through our pipeline of investigational drugs. Partnering with cancer experts and research institutions globally, we aim to improve our outstanding cancer to enable personalized care from early detection to precision medicine.
Menarini Stemline
Stemline Therapeutics GmbH
Grafenaustrasse 3, CH-6300 Zug – Switzerland
Linkedin https://www.linkedin.com/company/menarinistemline
Twitter: https://twitter.com/Stemline
www.menarinistemline.com
[email protected]
